[A17-46] Pembrolizumab (urothelial carcinoma) - Benefit assessment according to §35a Social Code Book V
|2017-12-15||Extract of dossier assessment||393 kB|
|2017-12-15||Dossier assessment (German version)||778 kB|
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Extract of dossier assessment
Federal Joint Committee (G-BA)
2018-08-02 A G-BA decision was published.